Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
Fujifilm has jettisoned its Japanese PIII trial investigating its antiviral Avigan (favipiravir) for the treatment of COVID-19 as the circulation of the Omicron variant has made it difficult to measure its efficacy for preventing severe disease. Fujifilm Toyama Chemical, a…
To read the full story
Related Article
- Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
- Plunge in COVID-19 Cases Stalling Japan Avigan Study by Few Months
November 5, 2021
- Fujifilm Launches New Japanese Avigan PIII Study for COVID-19
April 22, 2021
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
- Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…